ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS ATHE 深 滬
已收盤 08-08 16:00:00 美东时间
5.40
+0.090
+1.69%
華盛通- 最 高5.56
- 今 開5.17
- 成交量 3.70万股
- 最 低 5.17
- 昨 收 5.31
- 總市值 7993.84万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 1.001
- 委 比 -15.97%
- 總股本 1480.34万
- 歷史最高 51.50
- 量 比 1.20
- 振 幅 7.34%
- 歷史最低 1.001
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ather Energy Schedules Investor Meeting in Singapore
Ather Energy Limited ( ($IN:ATHERENERG) ) has shared an update. Ather Energy Li...
08-08 20:54
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported progress in its global Phase 3 program for treating hepatitis C virus (HCV) with the combination of bemnifosbuvir and ruzasvir. Patient enrollment in the C-BEYOND and C-FORWARD trials is on track, and Phase 2 results showed a 98% sustained virological response (SVR12). The regimen offers a short treatment duration, low drug-drug interaction risk, and convenience. The company also presented data at the EASL Congress, ...
08-07 20:05
Garmin announces collaborations with leading brands for Garmin Marathon Series
Companies will bring exciting activations to the expo, course and finish line festival OLATHE, Kan., Aug. 5, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Brooks, Dexcom, Maurten,...
08-05 19:03
Alterity Faces ASX Scrutiny Over Timing of Market-Sensitive MRI Study Announcement
Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's announcement titled ‘Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study'
08-04 19:59
Alterity Therapeutics Publishes Key Neuroimaging Measure for MSA
An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alte...
08-04 12:18
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Alterity Therapeutics announced the U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) and reported positive topline data from its Phase 2 clinical trials. The company highlighted robust efficacy, improved symptoms, and slowed disease progression in MSA patients. ATH434 demonstrated favorable safety profiles and target engagement through neuroimaging biomarkers. With a cash balance of A$40.66M, Alterity plans to adv...
07-30 11:25
【智能交通】信号机首次落地辽宁海城，国产技术再下一城！
近日，东土科技子公司东土正创智能交通产品成功进驻辽宁海城，搭载鸿道 操作系统的智能交通信号机与雅典娜1000（ATHENA）设备实现批量落地应用。这是东土科技在...
07-29 15:37
Alterity reports data from multiple system atrophy study
Alterity Therapeutics (NASDAQ:ATHE) shared positive results on Monday from a mid-stage trial of its main drug candidate, ATH434-202, to treat multiple system atrophy. During the trial, ATH434 showed p...
07-28 22:33
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
Alterity Therapeutics announces the publication of their MSA Atrophy Index (MSA-AI) in *Annals of Clinical and Translational Neurology*. Developed using deep learning, MSA-AI quantifies brain atrophy in MSA, enabling precise diagnosis and tracking of disease progression. The study highlights its effectiveness in distinguishing MSA from related disorders like Parkinson's disease and improving clinical trial design.
07-24 11:25
Hasbro's strong Q2 leads to upbeat FY25 outlook
Led by strong sales in its Wizards of the Coast and Digital Gaming units, Hasbro (NASDAQ:HAS) beat top- and bottom-line expectations for the second quarter and raised its full year revenue and profit ...
07-23 20:13
